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HOLESTEROL IS AN essential structural constituent of cellular membranes and also serves as a precursor for steroid hormones and bile acids. However, the accumulation of excess cholesterol can result in diseases such as atherosclerosis and gallstone formation. Thus, an appropriate balance must be maintained between de novo biosynthesis and dietary ingestion of cholesterol and its elimination from the body. Recently, the nuclear oxysterol receptors, liver X receptor (LXR)␣ and LXR␤, have been shown to have critical roles in the regulation of cholesterol balance (1, 2) . The LXRs are expressed in most tissues (3) (4) (5) (6) and are activated by various naturally occurring cholesterol derivatives including 24(S),25-epoxycholesterol, 22(R)-hydroxycholesterol, and 24(S)-hydroxycholesterol (7) (8) (9) (10) . The LXRs regulate the expression of target genes by binding to short stretches of DNA, termed LXRresponse elements (LXREs), as heterodimers with the 9-cis-retinoic acid receptors (RXRs) (3) (4) (5) (6) . During the past several years, LXREs have been identified in the regulatory regions of a number of genes involved in cholesterol homeostasis including CYP7A1 (9, 11) , which catalyzes the first and rate-limiting step in bile acid biosynthesis, cholesterol ester transport protein (12) , the transcription factor SREBP-1c (13, 14) , apolipoprotein (apo) E (15) , and the LXR␣ gene itself (16, 17) . LXREs have also been identified in the genes encoding the ATP binding cassette transporters (ABC) A1 and G1 (15, (18) (19) (20) (21) (22) , which mediate the efflux of phospholipids and cholesterol from macrophages, intestinal enterocytes, and other cell types. Thus, the LXR subtypes are important components of a complex regulatory system that senses cholesterol levels and modifies gene expression accordingly.
Although the central nervous system (CNS) accounts for less than 10% of total body mass, it contains approximately a quarter of all the unesterified cholesterol present in the body (23) . Virtually all of the cholesterol present in the brain is derived from in situ biosynthesis. The conversion of cholesterol to the LXR ligand 24(S)-hydroxycholesterol, which can cross the blood brain barrier and enter the general circulation, represents an important mechanism for cholesterol flux out of the CNS (24) (25) (26) . Importantly, the dysregulation of cholesterol balance in the brain may be related to the onset of neurological disease (23) . Cholesterol turnover across the brain is increased in neurodegenerative disorders such as Alzheimer's disease (AD) and Niemann-Pick type C disease (27, 28) . Moreover, there is clinical evidence that patients with elevated cholesterol levels have increased susceptibility to AD (29, 30) , and, conversely, that treatment with the statin class of cholesterol-lowering drugs reduces the incidence of AD (31, 32) . Finally, the E2 and E4 isoforms of apoE, which transports cholesterol throughout the body, have been genetically linked to either a decreased or increased risk of AD, respectively (33) (34) (35) . Thus, understanding the mechanisms regulating cholesterol balance in the brain may provide important insights into the etiology and treatment of neurodegenerative disorders.
Both LXR subtypes are expressed in the brain. LXR␤, in particular, is broadly expressed in the developing and adult rodent brain (36) . Interestingly, the LXR agonists 22(R)-hydroxycholesterol and 5-tetradecyloxy-2-furancarboxylic acid induce neuronal differentiation as measured by neurite outgrowth in rat pheochromocytoma cells (37) . However, the functions of the LXR subtypes in brain have remained largely unexplored. In this report, we have used potent, synthetic LXR agonists to investigate the role of these nuclear receptors in cholesterol homeostasis in the CNS.
RESULTS
As a first step in analyzing the role of the LXR subtypes in CNS, we compared their expression levels in hippocampus, cerebellum, and primary cultures of murine glia or neurons to those found in liver. Total RNA was prepared from tissues and cultures obtained from C57 Bl/6 mice and real time quantitative (RTQ)-PCR was used to profile the expression levels of LXR␣ and LXR␤. LXR␤ was expressed more abundantly in each of the CNS tissues/cells than in liver (Table 1) . By contrast, LXR␣ was expressed at lower, more variable levels in CNS tissue and cells than in liver (Table 1) . Notably, cultured neurons expressed very low levels of LXR␣. The LXR target genes ABCA1, ABCG1, and SREBP-1 were detected in each of the tissues/cultures examined (Table 1) . ABCG1 is implicated in cholesterol transport (38) , and its high basal expression in the brain suggests that it may have an important role in cholesterol homeostasis in this tissue. Overall, these results show that LXR␣, LXR␤, and several of their target genes are expressed in murine CNS tissue.
The expression of LXR␣ and LXR␤ in the CNS was also examined by in situ hybridization using probes specific for each receptor subtype. Serial coronal sections were prepared from mouse brain and mounted so that each slide contained forebrain, diencephalon, midbrain, and hindbrain with adjacent cortical and/or cerebellar regions. LXR␣ mRNA was detected in both glial cells and neurons in most subcortical regions but was generally absent from the cortex (Fig. 1, upper panel; and data not shown). In agreement with a previous study (36) , LXR␤ was widely expressed throughout the brain, where it was detected in both glial cells and neurons (Fig. 1, middle panel; and data not shown). Consistent with the RTQ-PCR data (Table 1) , LXR␤ appeared to be more highly expressed in the brain than LXR␣ (Fig. 1 , compare upper and middle panels; and data not shown).
We next examined whether the LXRs regulate cholesterol efflux in cells derived from the CNS. Efflux of [ 3 H]cholesterol was examined in pure primary cultures of glial or neuronal cells as well as in mixed glial-neuronal cultures. Cultured cells were treated with the potent, selective LXR agonist T0901317 (14) , the RXR agonist LG100268 (39) , or mixtures of these compounds. As shown in Fig. 2 , treatment with either T0901317 or LG100268 approximately doubled cholesterol efflux from cultured astrocytes. Efflux after combined treatment with the LXR and RXR agonists was not substantially greater than treatment with either agonist alone. Unlike primary macrophages or differentiated THP-1 cells, the astrocytes did not require addition of an exogenous cholesterol acceptor to detect either basal or druginduced cholesterol efflux. This may reflect that the cholesterol acceptor proteins apoE and apoA1 are both abundantly expressed in cultured astrocytes (data not shown). In contrast to its effects in astrocytes, T0901317 did not affect cholesterol efflux from pure neuronal cultures either in the absence (Fig. 2) or presence (data not shown) of added apoA1. As expected, an increase in cholesterol efflux was detected in mixed glial-neuronal cultures treated with the LXR and RXR agonists (Fig. 2) . Thus, the LXR agonist had a much more pronounced effect on gene expression in glial cells than in neurons.
Total RNA was prepared from the neuronal and glial cultures and used to profile expression patterns of the LXR target genes ABCA1, ABCG1, SREBP-1, and apoE. ABCA1, ABCG1, and SREBP-1 were up-regulated in response to the LXR agonist ( Fig. 3) , with more robust induction observed in astrocytes (black bars) than in neurons (white bars). By contrast, we observed no regulation of apoE in either neurons or glial cells (data not shown). In agreement with the efflux results ( Fig. 2 ), gene regulation in astrocytes was no greater in cultures cotreated with T0901317 and LG100268 than with the LXR agonist alone (Fig. 3) . The relatively weak induction of LXR target gene expression in neurons is consistent with the lack of drug-induced cholesterol efflux and may reflect the relative paucity of LXR␣ in these cells relative to cultured glia. By some estimates, at least 90% of the brain is composed of glia, many of them astrocytes (40) . That LXR activation influences cholesterol efflux from this important and prevalent cell type in vitro suggests that a similar and physiologically relevant regulation of cholesterol flux might occur in the CNS. To investigate whether LXR regulates genes involved in cholesterol flux in vivo, C57 Bl/6 mice were orally dosed for 3 or 7 d with T0901317, and their hippocampi and cerebella were removed for gene expression studies. Pharmacokinetic studies revealed that T0901317 was present in brain homogenates at concentrations of approximately 8 M (data not shown), which is well above the EC 50 value for activation of both LXR subtypes (14) . Expression of ABCA1 and SREBP-1 was significantly increased by drug treatment in both brain regions at both time points (Fig. 4) . ABCG1 expression was significantly increased in the cerebellum at the 3-d time point and in both the hippocampus and the cerebellum at the 7-d time point (Fig. 4) . ApoE was expressed at high levels in both regions of the brain; however, T0901317 had little or no effect on apoE expression (data not shown). Finally, the expression levels of LXR␣, LXR␤, and 24-hydroxylase, which produces the LXR ligand 24(S)-hydroxycholesterol, were not altered in any CNS tissue (data not shown). Together, these data demonstrate that the LXR signaling system is operative in the mouse CNS.
Fig. 1. Localization of LXR Subtypes in the Medial Thalamic Nucleus by in Situ Hybridization
Expression of LXR␣ (black silver grains; top panel) was observed in both glial cells (smaller densely stained nuclei) and neurons (large, less densely stained nuclei with prominent nucleoli). LXR␤ expression was also detected in glial cells and neurons (middle panel). Other than occasional background silver grains, the sense probe showed no positive signal in either cell type (bottom panel). 
DISCUSSION
In recent years, great strides have been made in understanding the functions of LXR␣ and LXR␤ in the regulation of cholesterol homeostasis. The LXRs regulate a number of genes involved in the biosynthesis, transport, and excretion of cholesterol and thus are likely to have important implications in human diseases such as hypercholesterolemia and atherosclerosis (2). However, the potential role that the LXRs might play in the CNS has remained largely undefined. The brain is the most cholesterol-rich organ in the body, and dysregulation of cholesterol homeostasis may influence neurological disorders such as AD (29-32, 41, 42) . The brain also produces virtually all of the body's 24(S)-hydroxycholesterol, a cholesterol metabolite that serves as an efficacious agonist of both LXR subtypes (7, 9, 24) . The expression patterns of cholesterol-24-hydroxylase, the enzyme that synthesizes 24(S)-hydroxycholesterol, and LXR␤ within the CNS are remarkably similar (4, 43) . These observations suggest that the LXRs might serve as integral components of a regulatory loop that modulates cholesterol levels and/or cholesterol partitioning in the brain.
Our studies demonstrate that an LXR agonist stimulates the expression of several established LXR target genes, including ABCA1, ABCG1, and SREBP-1, in the cerebellum and hippocampus of mice. Ligand treatment induced the expression of these same target genes and stimulated cholesterol efflux in cultured primary murine astrocytes. Notably, little or no effect was seen with the LXR agonist on either cholesterol efflux or LXR target gene expression in primary neuronal cultures. This may be a consequence of the Total RNA prepared from cultures treated as described in Fig. 1 was used to profile the expression of ABCA1, ABCG1, and SREBP-1. Expression levels for each gene in neurons (white bars) and astrocytes (black bars) were determined by RTQ-PCR and normalized to the vehicle-treated group. Similar results were obtained in at least two separate experiments.
Fig. 4. LXR Agonist Modulates Gene Expression in Mouse CNS
Mice (three per group) were treated by oral gavage for 3 or 7 d with vehicle or T0901317 as indicated. Total RNA was prepared from the hippocampus (white bars) and cerebellum (black bars) and analyzed for gene expression levels using RTQ-PCR. Expression levels for each gene were normalized to the average expression level in the vehicle group. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001 by t test relative to the vehicle group. lower expression levels of LXR␣ and LXR␤ in neurons compared with glia. Our findings are the first to demonstrate an effect of LXR activation on cholesterol metabolism in cells derived from the brain.
There is mounting evidence that cholesterol homeostasis is a key factor in CNS function (23) . Cholesterol turnover across the brain is increased in neurodegenerative disorders such as AD and Niemann-Pick type C disease (27, 28) , and there is clinical evidence that patients with elevated cholesterol levels have an increased susceptibility to AD (29) (30) (31) (32) . Recently, it was demonstrated that secretion of cholesterol complexed to apoE-containing lipoproteins from astroglial cells promotes synapse development in cultured CNS neurons (44) . These data are intriguing in light of the finding that the apoE4 isoform is associated with an increased risk of late-onset AD and a poor prognosis for recovery of neurological function after head trauma (34, 35, 45, 46) . Thus, drugs that affect cholesterol efflux such as LXR ligands may prove beneficial for the treatment of a range of CNS disorders.
In summary, we have demonstrated that LXR regulates a series of genes involved in cholesterol homeostasis in the CNS both in vitro and in vivo as well as cholesterol efflux from cultured astroglial cells. There is mounting evidence that cholesterol balance has an important impact on the onset and/or progression of various CNS disorders, including AD. Thus, LXR ligands may be useful in the treatment of a range of CNS disorders caused by either trauma or disease.
MATERIALS AND METHODS

Tissue Culture
Primary murine neuronal cultures were prepared from C57 Bl/6 mice essentially as previously described (47) . Embryonic d 18 fetuses were collected by cesarean section, their brains were removed, and the cerebral cortices were dissected from the rest of the brain. The tissue was rinsed during these steps several times in Ca 2ϩ -and Mg 2ϩ -free HBSS containing 1 mM HEPES (Life Technologies, Inc., Gaithersburg, MD). After the meninges were removed with forceps, the tissue was minced and incubated for 15 min at 37 C in 0.25% trypsin (Sigma, St. Louis, MO) in HBSS. The tissue was then washed twice in HBSS and twice in neuronal plating media [MEM containing 3 mg/ml glucose, 5% FBS (Life Technologies, Inc.), 5% horse serum (Life Technologies, Inc.), 100 U/ml penicillin/100 g/ml streptomycin (Irvine Scientific, Santa Ana, CA) and 2 mM glutamine (Irvine Scientific)] to which 10 g/ml deoxyribonuclease I (Sigma) had been added. The tissue was then triturated and spun at 3000 ϫ g for 10 min. The resulting cell pellet was resuspended in plating media, and trypan blueexcluding surviving cells were counted in a hemacytometer. Cells were plated into six-well plates at 1.35 ϫ 10 6 cells per well and maintained at 37 C in 5% CO 2 /95% air in a humidified incubator. The next morning, the plating media from some cultures were carefully withdrawn and replaced with serum-free media [Neurobasal media containing B27 supplement (both from Life Technologies, Inc.), 100 U/ml penicillin/ 100 g/ml streptomycin, and 0.5 mM glutamine]. These cells were fed by half-volume exchange with fresh serum-free media on d 3 in culture. Serum-free growth conditions restrict glial outgrowth such that the resulting cultures are more than 95% neuronal. The remaining cells were maintained in the same serum-containing plating media without media exchange to establish cultures composed of neurons and glia in an approximate ratio of 60:40 (47) . Cells were used in cholesterol efflux assays starting on culture d 6.
Murine astroglia were obtained from mice 1 d after birth. Mice were decapitated, their brains were removed, and the cerebral cortices were prepared as described above, except that astrocyte plating media was used [DMEM containing 4 mg/ml glucose, 5% FBS and 5% horse serum (Life Technologies, Inc. or Irvine Scientific), 100 U/ml penicillin/100 g/ml streptomycin, 25 mM HEPES, and 2-4 mM glutamine]. Glia were grown in T75 flasks at a density of approximately two brains per flask. Cells were fed once weekly by complete media exchange in maintenance media (DMEM containing 4.5 mg/ml glucose, 10% FBS, 100 U/ml penecillin/100 g/ml streptomycin, 25 mM HEPES, and 6 mM glutamine). By visual inspection, these cultures were nearly entirely astroglial with less than 1% contamination with microglia. After 7-14 d in vitro, cells were collected by trypsinization, counted in a hemacytometer, and plated into six-well plates at 50,000-100,000 cells per well in maintenance media. Cholesterol efflux assays were begun after 3 d of growth, at which time the cells were approximately 40% confluent.
In Situ Hybridization
Probes for LXR␣ and LXR␤ (500 and 411 bases long, respectively) were generated by RT-PCR and cloned into the transcription vector pGEM-T (Promega Corp., Madison, WI). After cloning, the vectors were linearized, and radiolabeled antisense transcripts were synthesized using SP6 (LXR␣) and T7 (LXR␤) RNA polymerase and [
33 P]rUTP (800 Ci/mol; Amersham Pharmacia Biotech, Arlington Heights, IL). A sense control probe was generated from the LXR␣ probe template by transcribing with T7 polymerase. Four C57 mice were transcardially perfused with 10% normal buffered formalin, embedded in paraffin, and sectioned at 8 m. Serial coronal sections were mounted so that each slide contained four sections: forebrain, diencephalon, midbrain, and hindbrain with adjacent cortical and/or cerebellar regions. The sections were mounted on plus slides, deparaffinized, rehydrated, and pretreated with 0.2 M HCl for 10 min, and then digested with 10 g/ml Proteinase K for 20 min and acetylated with 0.25% acetic anhydride in 0.1 M triethanolamine (pH 8.0) for 10 min. After dehydrating and drying, the sections were then prehybridized for 2 h in 50% prehybridization mix (600 mM NaCl, 40 mM Tris, pH 8.0, 10 mM EDTA, 2ϫ Denhardt's, 0.4% SDS, 20 mM dithiothreitol, 0.5 g/ml tRNA), and 50% formamide at 55 C. The probe (2 ϫ 10 6 cpm/section) was mixed with hybridization solution [2ϫ hybridization mix: 20% dextran sulfate in formamide, 1:1 (vol/vol)] and hybridized overnight at 55 C. The following day the sections were washed at 55 C in 5ϫ salt-sodium citrate (SSC) (1ϫ SSC ϭ 150 mM NaCl, 15 mM Na citrate) for 1 h and 0.1ϫ SSC for 30 min, and then digested with ribonuclease A (20 g/ml) at 37 C for 30 min, washed again in 0.1ϫSSC at 55 C for 30 min, and dehydrated. After drying, the slides were dipped in Kodak NTB-2 emulsion (Eastman-Kodak, Rochester, NY), exposed for 2-4 wk, developed with Kodak D-19 developer, counterstained with hematoxylin, and then examined by both dark-field and bright-field microscopy.
Cholesterol Efflux Assays
Cholesterol efflux assays were performed as described elsewhere (48) with minor modifications. For astrocytes, the culture media were removed and replaced with 1 ml/well DMEM containing 4.5 mg/ml glucose, 5% FBS, 100 U/ml penecillin/ 100 g/ml streptomycin, 25 mM HEPES, and 6 mM glutamine supplemented with 0.5% BSA and 5 l [1,2-3 H(N)]-choles-terol (1 mCi/ml ethanolic stock). Twenty-four hours later, cells were washed once in serum-free DMEM containing glucose, penicillin/streptomycin, HEPES, and glutamine and then incubated for 24 h in the same media supplemented with 0.5% BSA and various drugs or dimethylsulfoxide vehicle. The next day, cells were washed twice in serum-free media and then incubated for a further 24 h in serum-free media supplemented with drugs or dimethylsulfoxide. Human apoA1 was added to some culture dishes to serve as an exogenous cholesterol acceptor molecule. At the end of this incubation, culture media were collected and spun in a microfuge. Adherent cells were washed three times in PBS and extracted for 1 h in 1 ml/well hexane-isopropanol (3:2 vol/vol). Two hundred microliters of the culture media supernatant and 200 l of the cell extract were counted for tritium in 2 ml Packard Ultima Gold Scint (Packard Bioscience, Meriden, CT). Cholesterol efflux from neurons was examined in much the same way except that cells were always washed and incubated with the neuronal serum-free culturing media described above. On the first day of the efflux experiment, neuronal culture dishes received a half-volume media change with media containing 10 l [1,2-3 H(N)]-cholesterol. In all experiments, control culture dishes received an equal volume of ethanol instead of [1, [2] [3] H(N)]-cholesterol on the first day. These culture dishes were subsequently treated in parallel with [1, [2] [3] H(N)]-cholesterol-loaded culture dishes for purposes of collecting RNA for gene expression studies.
Animal Studies
All procedures performed were in compliance with the Animal Welfare Act and US Department of Agriculture regulations and were approved by the GlaxoSmithKline Institutional Animal Care and Use Committee. Adult male C57 Bl/6 mice were dosed by oral gavage with 50 mg/kg/d of T0901317 (2) or vehicle (0.5% methylcellulose). After 2 or 7 d of treatment, animals were euthanized and their brains were removed. The cerebellum and both hippocampi were dissected and snap frozen in liquid nitrogen for RNA isolation.
Determination of Drug Tissue Concentrations
To determine [ 3 H]cholesterol concentrations, tissues and serum samples were analyzed by HPLC with a radioactivity detector. Briefly, tissues (300 mg) were homogenized in 2 ml 0.25 M HEPES, pH 7.4, containing 1.15% KCl. Aliquots of serum and homogenized tissues were removed for total tritium counting by scintillation and the remainder was shaken for 20 min at room temperature in 3 ml choloroform-methanol (2:1) containing 5 mg/ml butylated hydroxytoluene. Samples were spun in a tabletop centrifuge for 20 min at 2,000 rpm and the organic phase was evaporated under nitrogen. The residue was dissolved in HPLC mobile phase solution (99% hexane, 1% methyl t-butyl ether) and analyzed with a normal-phase HPLC system [Bondclone uPoracil silica column (Phenomenex, Inc., Torrance, CA); gradient elution from 10-75% methyl t-butyl ether in hexane] equipped with a Radiomatic FLO-ONE detector (Packard Bioscience). Peaks corresponding to cholesterol, choleseryl ester, and oxysterols were identified by coelution with known standards.
T0901317 (14) concentrations were measured in brain tissue using HPLC with mass spectrometric detection. Tissue homogenates were homogenized in 2 vol of water. Aliquots of the homogenate were extracted with 4 vol of acetonitrile containing an internal standard. After centrifugation, the supernatant was evaporated to dryness and then dissolved in HPLC mobile phase. T0901317 was eluted from an HPLC column [Hypersil phenyl, 2 ϫ 50 mm, 5 m (Keystone Scientific, Inc., Bellafonte, PA)] using a mobile phase consisting of 5 mM ammonium acetate (pH 4), methanol, and acetonitrile. T0901317 product ions (MϩH ϭ 181 m/z and 141 massto-charge ratio, respectively) were measured using a Finnigan TSQ 7000 mass spectrometer (Thermo Finnigan, San Jose, CA) after ionization by atmospheric pressure chemical ionization. Tissue standards were prepared by adding T0901317 to blank tissue homogenates. HPLC with mass spectrometric detection responses was used to construct a peak area ratio (T0901317 peak area/internal standard peak area) vs. tissue homogenate concentration calibration curve. Tissue concentrations were expressed as micromoles/g tissue; approximate tissue concentrations were calculated assuming 1 g of tissue occupies a volume of 1 ml.
RNA Isolation
Total RNA was isolated from tissue and cell culture samples using TRIzol reagent (Life Technologies, Inc.) according to the manufacturer's protocol. To facilitate recovery of nucleic acid, 100 g glycogen (Ambion, Inc., Austin, TX) was added. Samples were resuspended in ribonuclease-free water and stored at Ϫ70 C.
RTQ-PCR
Total RNA samples were diluted to 100 g/ml and treated with 40 U/ml RNA-free deoxyribonuclease I (Ambion, Inc.) for 30 min at 37 C followed by inactivation at 75 C for 5 min. Samples were quantitated by spectrophotometry or with the RiboGreen assay (Molecular Probes, Inc., Eugene, OR) and diluted to a concentration of 10 ng/l. Samples were then assayed in duplicate or triplicate 25-l reactions using 25 ng RNA/reaction with Perkin-Elmer Corp. chemistry on an ABI Prism 7700 (Perkin-Elmer Corp., Norwalk, CT) according to the manufacturer's instructions. Gene-specific primers were used at 7.5 or 22.5 pmol/reaction and the gene-specific probe was used at 5 pmol/reaction. Primers and probe were synthesized by Keystone Laboratories (Camarillo, CA). Fold induction values were calculated by subtracting the mean threshold cycle number (Ct) for each treatment group from the mean Ct for the vehicle group and raising 2 to the power of this difference. The following primer/probe sets were used: 
